Celgene Has A Swift Start For Pomalyst Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech did better than Wall Street expected with its first sales figures for multiple myeloma drug Pomalyst. But it’s still very early going. Continuing to expand its hematology oncology franchise, including main revenue-driver Revlimid, remains a primary focus for Celgene.